Healthcare -
Medical - Devices - NASDAQ - US
$ 1.58
-2.52 %
$ 93.6 M
Market Cap
-3.69
P/E
1. INTRINSIC VALUE
Balance Sheet
Vivani Medical, Inc.
| Current Assets | 20.4 M |
| Cash & Short-Term Investments | 18.4 M |
| Receivables | 253 K |
| Other Current Assets | 1.84 M |
| Non-Current Assets | 21.1 M |
| Long-Term Investments | 0 |
| PP&E | 19.6 M |
| Other Non-Current Assets | 1.47 M |
| Current Liabilities | 5.99 M |
| Accounts Payable | 817 K |
| Short-Term Debt | 1.35 M |
| Other Current Liabilities | 3.82 M |
| Non-Current Liabilities | 18 M |
| Long-Term Debt | 18 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Vivani Medical, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 24.7 M |
| Operating Income | -24.7 M |
| Other Expenses | -1.19 M |
| Net Income | -23.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Vivani Medical, Inc.
| Net Income | -23.5 M |
| Depreciation & Amortization | 400 K |
| Capital Expenditures | -556 K |
| Stock-Based Compensation | 1.61 M |
| Change in Working Capital | 354 K |
| Others | 442 K |
| Free Cash Flow | -21.3 M |
Wall Street Analysts Price Targets
Vivani Medical, Inc.
VANI has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
VANI does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Vivani Medical, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
14 K USD 1
0-3 MONTHS
258 K USD 2
3-6 MONTHS
5 M USD 1
6-9 MONTHS
14 K USD 1
9-12 MONTHS
7. News
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
zacks.com
- 1 month ago
I Missed The Quantum Rally - I Won't Miss The Next One
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
seekingalpha.com
- 2 months ago
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025
globenewswire.com
- 2 months ago
Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists' (AAPS) “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop, taking place from May 13-14, 2025.
globenewswire.com
- 2 months ago
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans
globenewswire.com
- 3 months ago
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025
globenewswire.com
- 3 months ago
Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a private placement.
globenewswire.com
- 3 months ago
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant)
globenewswire.com
- 3 months ago
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on March 27, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investment community.
businesswire.com
- 4 months ago
What Makes Vivani Medical (VANI) a New Buy Stock
Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 4 months ago
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1™ clinical trial. This milestone marks a critical step toward addressing one of healthcare's most pressing challenges: medication adherence in metabolic diseases including chronic weight management an.
businesswire.com
- 4 months ago
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current.
businesswire.com
- 4 months ago
8. Profile
Summary
Vivani Medical, Inc. VANI
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 93.6 M
Dividend Yield
0.00%
Description
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
Contact
5858 Horton Street, Alameda, CA, 94608
https://www.vivani.com
IPO
Date
Nov. 19, 2014
Employees
37
Officers
Mr. Truc Le M.B.A.
Chief Operations Officer
Dr. Adam Mendelsohn Ph.D.
Co-Founder, Chief Executive Officer & Director
Dr. Lisa E. Porter M.D.
Chief Medical Officer
Mr. Donald Dwyer M.B.A.
Chief Business Officer & Corporate Secretary
Ms. Brigid Ann Makes M.B.A.
Chief Financial Officer and Principal Financial & Accounting Officer